Source: Eur Respir J 2007; 30: 821-822



Rating:

Share or cite this content

Citations should be made in the following way:
Bakker J. A., Bierau J., Drent M.. Therapeutic regimens in interstitial lung disease guided by genetic screening: fact or fiction?. Eur Respir J 2007; 30: 821-822

Member's Comments

No comment yet.

Related content which might interest you: What’s new in interstitial lung diseases in children? Source: Virtual Congress 2021 – Paediatric year in review Year: 2021 Diagnosis of interstitial lung diseases and impact of guidelines: an issue only for pulmonologists? Source: Annual Congress 2007 - Controversies in the management of interstitial lung diseases Year: 2007 Interstitial lung diseases and COVID-19: myths and reality Source: Virtual Congress 2021 – Chinese programme 2021 Year: 2021 Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing? Source: Eur Respir J 2014; 44: 1011-1022 Year: 2014 Treatment of early lung disease – is it possible? Does it work? Source: Annual Congress 2004 - PG19 - Screening for cystic fibrosis: diagnose early - treat early Year: 2004 The future of treatment for interstitial lung diseases: the patient’s and physician’s perspective Source: International Congress 2019 – Rare lung diseases Year: 2019 New antifibrotic drugs: will interstitial diseases patients still need lung transplantation? Source: Virtual Congress 2020 – Lung transplantation in the era of new drugs Year: 2020 Targeted therapies for lung cancer: how did the game begin? Source: Breathe 2016; 12: 177-179 Year: 2016 Advances in treatment of complex lung disease: will targeted therapy with anticalins be clinically applied in the near future? Source: International Congress 2019 – Inhaled medicines and biological therapies in the current era of systemic treatments Year: 2019 Lung disease induced by newer therapies for lung cancer: an update Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006 Severe fibrotic lung disease – How much therapy is too much therapy? Source: Annual Congress 2008 - Clinical Grand Round - an interactive session Year: 2008 Interstitial lung disease: new challenges and evolving phenotypes Source: Eur Respir Rev 2009; 19: 91-93 Year: 2010 Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence Source: Eur Respir Rev, 27 (150) 180074; 10.1183/16000617.0074-2018 Year: 2018 Multidisciplinary board for interstitial lung disease: Relevance for real life? Source: International Congress 2015 – New insights into IIPs Year: 2015 Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options Year: 2021 Novel aspects in lung cancer pathology: how does it help for selecting chemotherapy? Source: Annual Congress 2010 - PG4 Core Curriculum Postgraduate Course: Pathology for the clinician Year: 2010 Diffuse parenchymal lung disease: a practical overview Is a lung biopsy necessary for management? Source: Breathe 2008; 4: 233-239 Year: 2008 Radiological diagnosis of interstitial lung disease: is it all about pattern recognition? Source: Eur Respir J, 52 (2) 1801321; 10.1183/13993003.01321-2018 Year: 2018